艾迪注射液联合紫杉醇注射液对老年非小细胞肺癌的疗效及安全性分析

Efficacy and safety of Aidi injection combined with Paclitarel injection in the treatment of elderly patients with non-small cell lung cancers

目的观察分析艾迪注射液联合紫杉醇注射液治疗老年非小细胞肺癌的疗效及安全性。方法选择2016年1月至2017年6月本院收治的老年非小细胞肺癌患者94例为研究对象。按照随机数表法将其分为对照组和观察组,每组各47例。在常规化疗的基础上,对照组患者加用紫杉醇注射液,观察组患者加用艾迪注射液联合紫杉醇注射液。观察并比较两组患者的临床疗效、肺功能及不良反应发生率。结果观察组患者治疗总有效率显著高于对照组(P<0.05);治疗后,两组患者第一秒用力呼气量(forced expiratory volume in first second,FEV_1)、用力肺活量(forced vital capacity,FVC)、FEV_1占FVC的百分比(FEV_1/FVC)均明显高于治疗前(P<0.05),且观察组上述指标水平均显著高于对照组(P<0.05);两组患者肝功能损伤、神经毒性、过敏以及脱发发生率比较均无显著差异(P>0.05);观察组患者骨髓抑制、胃肠道反应发生率均显著低于对照组(P<0.05)。结论在化疗基础上加用艾迪注射液联合紫杉醇注射液可有效提高老年非小细胞肺癌患者的临床疗效,并降低骨髓抑制和胃肠道反应的发生率。

Objective To study the efficacy and safety of Aidi injection combined with Paclitarel injection in the treatment of elderly patients with non-small cell lung cancer. Method 94 cases of elderly patients with non-small cell lung cancer who were admitted to our hospital from January 2016 to June 2017 were selected and divided into control group and observation group according to the random number table method, with 47 cases in each group. On the basis of conventional chemotherapy, the patients in control group were treated with Paclitaxel injection, and patients in observation group were treated with Aidi injection combined with Paclitaxel. The clinical efficacy, pulmonary function and the incidence of toxic and side effects after treatment were observed and compared in both groups. Result The total effective rate of observation group was higher than that of control group（P〈0.05）. After treatment, the forced expiratory volume in first second（FEV1）, forced vital capacity（FVC）, FEV1/FVC levels in the two groups were higher than before treatment（P〈0.05）, and the above indexes of observation group was higher than control group（P〈0.05）. There was no significant difference in the incidence of hepatic impairment, neurotoxicity and anaphylaxis and alopecia between the two groups（P〉0.05）. The incidence of myelosuppression and gastrointestinal reactions of observation group was lower than that of control group（P〈0.05）. Conclusion Aidi injection combined with Paclitaxel injection can effectively improve the clinical efficacy of elderly patients with non-small cell lung cancer, and it can reduce the incidence of obvious adverse reactions such as myelosuppression, gastrointestinal reactions and other secondary degrees.